Open AccessPost-transplant lymphoproliferative disorder: Case reports of three children with kidney transplant
Author(s) -
Brankica Spasojević,
Amira PecoAntić,
Dušan Paripović,
D Kruscić,
Zoran Krstić,
Maja Ćupić,
Mirjana Cvetković,
Gordana MiloševskiLomić,
Mirjana Kostić
Publication year - 2014
Publication title -
srpski arhiv za celokupno lekarstvo
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.135
H-Index - 17
eISSN - 2406-0895
pISSN - 0370-8179
DOI - 10.2298/sarh1402083s
Subject(s) - medicine , immunosuppression , rituximab , lymphoproliferative disorders , post transplant lymphoproliferative disorder , lymphoma , immunology , transplantation , lymphoid hyperplasia , disease , epstein–barr virus , pathology , gastroenterology , virus
Post-transplant lymphoproliferative disorder (PTLD) is a heterogeneous group of diseases, characterized by abnormal lymphoid proliferation following transplantation. It is a disease of the immunosuppressed state, and its occurrence is mostly associated with the use of T-cell depleting agents, and also intensification of immunosuppressive regimens. In the majority of cases, PTLD is a consequence of Epstein-Barr virus (EBV) infection and is a B-cell hyperplasia with CD-20 positive lymphocytes. The 2008 World Health Organization classification for lymphoid malignancies divides PTLD into four major categories: early lesions, polymorphic PTLD, monomorphic PTLD and Hodgkin PTLD. The treatment and prognosis depend on histology. The cornerstone of PTLD therapy includes reduction/withdrawal of immunosuppression, monoclonal anti CD-20 antibody (rituximab) and chemotherapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom